What’s the Difference Between RCT Evidence and Patient Registries for Cannabis?

The landscape of medical cannabis in the UK is complex and Find more information often confusing for patients, prescribers, and even policymakers. Since the 2018 rescheduling of cannabis-based https://highstylife.com/how-do-i-find-a-legit-medical-cannabis-clinic-in-the-uk/ products for medicinal use (CBPMs), many assumptions have formed about what evidence supports their use, especially when it comes to the types of data—randomised controlled trials (RCTs) versus patient registries—that inform clinical decisions.

In this post, we’ll untangle the difference between RCT evidence and patient registries specifically for cannabis, explain why the 2018 rescheduling mattered, clarify the gulf between legal prescribing and NHS funding, and cover the rules around specialist-only prescribing and unlicensed cannabis-based medicines.

To help you navigate next steps if you’re considering treatment, we’ll also highlight trusted resources like medicalcannabis.co.uk (a clinic directory and comparison site) and the explainer from releaf.co.uk.

The 2018 Rescheduling: What Changed and Why It Matters

Before November 2018, cannabis was classified as a Schedule 1 drug under the Misuse of Drugs Regulations 2001 in the UK, meaning it had “no recognised medicinal use” and could only be used for research purposes. This restricted medical use and official prescribing to almost nil.

The 2018 rescheduling reclassified cannabis-based products for medicinal use as Schedule 2 drugs. That made it legally possible for specialist doctors to prescribe cannabis-based medicines—under strict conditions—but did not mean that these treatments automatically became available on the NHS. This distinction is key:

Legality: Post-2018, prescribing cannabis-based medicines became legal via specialist doctors.
Funding: NHS funding remains very limited; most patients must self-fund treatment privately.

While legal prescribing opened the door to access cannabis-based medicines, NHS England’s cautious approach means only very rare cases receive treatment funded by the health service. This is mainly due to limited high-quality evidence on cost-effectiveness (more on that shortly).

Specialist-Only Prescribing Rules: Keeping Tight Control

Under current regulations, only doctors on the General Medical Council (GMC) specialist register can prescribe cannabis-based products for medicinal use. General practitioners (GPs) cannot prescribe these drugs directly, although they may continue prescribing after specialist initiation.

This reflects regulatory caution surrounding CBPMs, given their unclear evidence base compared to established medicines and the need to mitigate prescribing risks (dosages, side effects, efficacy uncertainties).

Evidence Hierarchy in Medicine: Why Randomised Controlled Trials Reign Supreme

In evidence-based medicine, randomised controlled trials (RCTs) are generally considered the “gold standard” for establishing whether treatments work. At its simplest, an RCT randomly assigns participants to two or more groups—typically a treatment arm and a placebo or control arm—and measures outcomes while minimising bias.

RCTs’ strength comes from controlling confounding variables, blinding doctors and patients, and pre-specifying outcomes. This approach produces robust, reproducible evidence for drug approval and prescribing guidelines.

Randomised Controlled Trial Cannabis: What We Have So Far

For cannabis-based products, RCT evidence remains limited and often contradictory. Some RCTs have shown benefits in specific conditions such as multiple sclerosis spasticity and certain types of chronic pain, but many studies are small, short-term, or have methodological issues. The uncertainty means regulators and NICE have been reluctant to broadly recommend cannabis-based medicines.

This lack of a strong RCT base also undermines the ability to secure broad NHS funding for these medicines, particularly expensive formulations.

What are Patient Registries (Observational Registries) and Why Do They Matter?

Patient registries collect “real-world” data on outcomes, side effects, and usage patterns from patients prescribed cannabis-based medicines outside of trials. They are observational, meaning patients and doctors decide treatment, and data is gathered retrospectively or prospectively without controls or randomisation.

Registries provide valuable insights into how CBPMs work in everyday clinical practice, especially for patients who don’t qualify for trials or rare conditions where large RCTs are impractical.

For example, medicalcannabis.co.uk highlights ongoing registries tracking patient outcomes, including symptom relief and side effects. These help build up a bigger picture of cannabis use but cannot prove causation in the same way RCTs can.

Observational Registry Cannabis: Pros and Cons

Pros: Reflects real-life patients with diverse conditions; can capture long-term data; supports hypothesis generation.
Cons: Prone to bias (selection bias, reporting bias); no control group for direct comparison; cannot establish definitive treatment efficacy.

Unlicensed Cannabis-Based Medicines and NHS Caution

Most cannabis-based medicines prescribed in the UK remain unlicensed “specials”—custom-made formulations supplied on a named-patient basis rather than licensed, approved drugs. While legal, these unlicensed products come with extra regulatory caution:

They do not have formal MHRA marketing authorisation.
Prescribers must assess risks versus benefits carefully.
NHS funding is usually not available unless in very exceptional circumstances.

Due to this, patients often turn to private clinics featured on medicalcannabis.co.uk to access treatment. Clinics' pricing varies widely – no fixed NHS price benchmarks exist yet. If future sources specify prices, quoting exact figures with full attribution is essential since affordability impacts access greatly.

NHS Funding vs Legal Prescribing: What Patients Need to Know

It’s critical to understand the difference between:

Legal prescribing: A specialist doctor can legally prescribe cannabis-based medicines after thorough clinical assessment.
NHS funding: NHS England funds cannabis-based medicines only in very limited, exceptional cases where other treatments have failed and sufficient high-quality evidence supports effectiveness.

For the vast majority, legal prescribing means going private, paying out-of-pocket, and engaging in ongoing monitoring and potential switching of medicines based on clinical effect and side effects.

Summary Table: Comparing RCT Evidence and Patient Registries for Cannabis

Criteria Randomised Controlled Trial (RCT) Patient (Observational) Registry Design Random allocation, control group, blinding Observational, no randomisation, no control group Purpose Prove causality, assess efficacy/safety under controlled conditions Collect real-world data on outcomes, safety, and usage Strengths Minimises bias, highest evidence quality, basis for guidelines Reflects everyday clinical practice, captures long-term and diverse patient data Limitations Expensive, time-consuming, often narrow patient groups Susceptible to bias, no proof of causality, variable data quality Relevance for UK Cannabis Prescribing Limited existing RCTs restrict NHS guideline adoption Increasingly important to supplement evidence, inform clinical practice

Where to Find Reliable Information and Clinics

If you’re exploring medical cannabis, it helps to use reputable sources. The medicalcannabis.co.uk directory lists UK clinics, breaking down services, conditions treated, and patient reviews—helpful for comparison shopping.

For easy-to-understand guides on cannabis medicines, evidence levels, and prescribing regulations, the releaf.co.uk website offers clear explainer articles to demystify jargon and myths.

Final Thoughts

Understanding evidence types—RCTs and patient registries—is crucial if you’re considering cannabis-based medicines. While RCTs provide robust evidence needed to guide NHS prescriptions and large-scale approvals, real-world patient registries help fill gaps and track safety in everyday use.

Because cannabis prescribing remains specialist-only and mostly unfunded by the NHS, a careful, informed conversation with a specialist doctor is your best next step. Use specialist directories and trusted educational resources to ensure you know exactly what you’re getting into—including cost, legal status, and evidence backing the treatment you’re offered.

Remember, legal access isn’t the same as easy access, and no cannabis medicine is yet an NHS standard treatment widely funded. Clarity on evidence and costs will help you make the decisions that matter.